Company: Aurobindo Pharma Ltd. Category: IPO Notes


ARBP shines with a steady track record for resolving plant related issues and moving up the value chain with more number of approvals in complex drugs.
April 4, 2019, 11:53 a.m.
Publisher: plindia.com

Aurobindo Pharmaceuticals (APL) has a big relief in form of Establishment Inspection report (EIR) for Unit-4 facility in which the USFDA has closed issued Form 483.
March 13, 2019, 11:26 a.m.
Publisher: angelbroking.com

Aurobindo Pharma (ARBP) would acquire seven marketed oncology products, intellectual property and commercial infrastructure from Spectrum Pharma for a consideration of USD300m, which includes an upfront payment of USD160m and a milestone-linked payment of USD140m.
Jan. 17, 2019, 11:32 a.m.
Publisher: motilaloswal.com

Net Sales are expected to increase by 15.8 percent Y-o-Y (up 5.7 percent Q-o-Q) to Rs. 5,022.3 crore, according to ICICI Direct.
Jan. 11, 2019, 5:23 p.m.
Publisher: moneycontrol.com


We believe ARBP is likely to benefit from Pfizer’s rationalization of two injectable plants in India, which are key contributors in limited competition drugs, Tazo+Pip and Penems.
Jan. 10, 2019, 11:51 a.m.
Publisher: plindia.com

For 2QFY2019, Aurobindo Pharma (APL), the company posted sales of Rs. 4,667cr v/s. Rs. 4,354cr in 2QFY2018, a yoy growth of 7.2%. On the operating front, the EBITDA margin came in at 18.8% v/s. 23.8% in 2QFY2018.
Nov. 17, 2018, 10:54 a.m.

ARBP’s performance in Q2FY19 were in-line with our estimates as its net sales, adj. EBITDA and PAT increased by 12%, 33% and 34% QoQ respectively.
Nov. 13, 2018, 11:20 a.m.
Publisher: plindia.com

Aurobindo Pharma’s (APL) 2QFY19 revenues (Rs47,514mn) were 9.6%/4.4% above our/consensus estimates, respectively.
Nov. 13, 2018, 11:18 a.m.
Publisher: nirmalbang.com

Aurobindo Pharma (ARBP) has delivered a better-than-expected performance on all metrics in 2QFY19.
Nov. 13, 2018, 11:10 a.m.
Publisher: trade.rsec.co.in

Aurobindo Pharma’s (APL) acquisition of Sandoz’s product portfolio (dermatology and oral solids) for US$900mn will fetch a similar amount in incremental sales (30% from dermatology products and the rest from oral solids) in the first full year post transaction closure (six to nine months from the announcement).
Sept. 10, 2018, 11:20 a.m.
Publisher: nirmalbang.com

-->